Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542
Status at this site: Recruiting
- Conditions
- Crohn's Disease
- Interventions
- Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 64
- States / cities
- Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more